AU Patent

AU2017352206B2 — Methods of treatment with deuterated CFTR potentiators

Assigned to Vertex Pharmaceuticals Europe Ltd · Expires 2022-03-03 · 4y expired

What this patent protects

Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator. The method comprises administering to the subject Compoind (I) or pharmaceutically acceptable salts thereof, together with food. A…

USPTO Abstract

Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator. The method comprises administering to the subject Compoind (I) or pharmaceutically acceptable salts thereof, together with food. Also disclosed are products comprising Compound (I) and the use of such products.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017352206B2
Jurisdiction
AU
Classification
Expires
2022-03-03
Drug substance claim
No
Drug product claim
No
Assignee
Vertex Pharmaceuticals Europe Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.